(Nasdaq: CNXU) has taken another step toward a planned first-quarter 2027 FDA 510(k) filing by advancing manufacturing scale-up, transferring standardized formulation methods to a contract development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results